irinotecan
Onco
Daily
Twitter
Facebook
Youtube
RSS Feed
Linkedin
Facebook
RSS
Twitter
Youtube
Linkedin
July, 2024
July 2024
M
T
W
T
F
S
S
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
« Jun
irinotecan
Jul 11, 2024, 09:55 |
Insight
Piotr Wysocki: Tisotumab vedotin improves outcomes of patients with recurrent cervical cancer
Piotr Wysocki recently posted on LinkedIn: "Vergote I et al. published results of a phase III…
Jul 3, 2024, 14:37 |
Insight
Jarushka Naidoo: Phase III RESILIENT Trial of Liposomal Irinotecan v Topotecan in 2L SCLC
Jarushka Naidoo shared a post on X: “Phase III RESILIENT Trial of Liposomal Irinotecan v…
Jun 23, 2024, 03:27 |
Drugs
Mark Lewis: Remember I before O
Mark Lewis shared on X: "When using chemo regimens that contain both irinotecan and oxaliplatin,…
Jun 16, 2024, 01:22 |
Insight
Ruzanna Papyan: Week 4 of the Global Access To Anti-GD2 Campaign
Ruzanna Papyan shared on LinkedIn: "Week 4 of the Global Access To Anti-GD2 Campaign This week,…
Jun 9, 2024, 14:57 |
Blog
No survival advantage for first-line liposomal irinotecan patients with pancreatic adenocarcinoma
Mark Lewis shared on X: "Important abstract (GIANT, or EA2186) from ASCO24 which does NOT show…
Apr 25, 2024, 12:40 |
Drugs
Piotr Wysocki: Similar activity of topotecan and liposomal irinotecan in second-line treatment of SCLC
Piotr Wysocki, Professor of Medicine and Head of the Department of Oncology at Jagiellonian University…
Apr 17, 2024, 13:11 |
Insight
New Paper Alert! Exploring Treatment Strategies After Progression to BRAF V600E-Targeted Therapy in Metastatic Colorectal Cancer: A Real-World Analysis
New Paper Alert: Exploring Treatment Strategies After Progression to BRAF V600E-Targeted Therapy in Metastatic Colorectal…
Apr 16, 2024, 11:36 |
Insight
Piotr Wysocki: Rechallenge with anti-EGFR antibodies is a feasible and safe strategy in refractory metastatic colorectal cancer patients with RAS/BRAFwt ctDNA
Piotr Wysocki, Professor of Medicine and Head of the Department of Oncology at Jagiellonian University…
Apr 11, 2024, 15:23 |
Drugs
Piotr Wysocki: Adagrasib and cetuximab in KRAS G12C-mutated colorectal cancer is a safe and active
Piotr Wysocki, Professor of Medicine and Head of the Department of Oncology at Jagiellonian University…
All:
9
Posts:
1 - 100
The largest philanthropic partnership in The V Foundation’s history - Dolphins Cancer Challenge
Glecirasib: A Promising Novel KRAS G12C Inhibitor in Clinical Development
How the Médecins Sans Frontières Journal Inspired a Lifetime of Humanitarian Service: Paul Spiegel
OncoDaily Party and Yvonne Award Photos - Part 1
Michael Douglas: The Untold Story of His Battle Against Cancer
Facebook
RSS Feed
Twitter
Linkedin
Youtube